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	 Tuberculosis	(TB)	is	the	most	common	opportunistic	
infection among human immunodeficiency virus 
(HIV)-infected persons living in developing countries1-4,	
and is the most common cause of mortality5.	Incident	
TB,	often,	is	the	index	illness	leading	to	a	diagnosis	of	
underlying HIV infection in these patients. In fact, the 
World	Health	Organization	 (WHO)	 recommends	 that	
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Background & objective: Many patients presenting with tuberculosis (TB) have underlying human 
immunodeficiency virus (HIV) co-infection. Routine HIV testing, however, is not a component of the 
national TB control programme in India. We sought to derive and validate a clinical prediction rule, 
based on clinical and laboratory parameters, to identify patients at high risk for HIV co-infection among 
those treated for active TB.
Methods: Case records of adult patients with active TB treated between 1997 and 2003 at the All 
India Institute of Medical Sciences hospital, New Delhi were retrospectively reviewed. The data set 
was randomly split into a training set and a testing set. First a clinical prediction rule was derived by 
multivariable logistic regression on the training set and was subsequently validated on the testing set.
Results: The study group comprised 1074 patients [training set 711 (66%), HIV co-infected 66 (9%); testing 
set 363 (34%), HIV co-infected 30 (8%)]. In the training set, male gender [odds ratio (95% CI) 5.31(1.52-
18.61)], axillary lymphadenopathy [9.71 (3.24-29.10)], anaemia [7.56 (2.48-23.05)], hypoalbuminaemia 
[3.67(1.31-10.26)], and reduced triceps skinfold thickness [2.91(0.95-8.89)] were independently associated 
with HIV co-infection. In the testing set, presence of any two of these five features was 94 per cent 
(95% CI 84-100%) sensitive and 54 per cent (49-60%) specific for predicting HIV co-infection; negative 
predictive value was 99 per cent (98-100%). Area under the receiver-operating characteristic curve was 
0.93 (0.86-1.0) in the testing set.
Interpretation & conclusions: A simple clinical prediction rule based on clinical and laboratory parameters 
could be used to identify a subgroup of patients, among those treated for active TB in a hospital setting, 
for targeted HIV testing.
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in countries with a generalised or concentrated HIV 
epidemic, all patients with active TB should be offered 
HIV	 testing6. Even with optimal anti-TB treatment, 
HIV co-infected patients with active TB (HIV-TB) are 
at	a	higher	risk	of	death	and	recurrent	TB	as	compared	
to HIV-negative patients with TB7-9. Apart from early 
access to antiretroviral treatment, if detected at the time 
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of presentation with TB, patients with HIV-TB might 
benefit from interventions such as co-trimoxazole and 
post-treatment isoniazid preventive therapies10,11.
 Recently, the algorithmic approach to the diagnosis 
of sputum-smear negative TB in HIV-infected 
individuals has been revised12. In view of this change, 
in	 addition	 to	 HIV	 testing	 of	 patients	 diagnosed	
having TB (i.e.,	TB	cases),	the	WHO	has	extended	its	
recommendations	 for	 routine	 HIV	 testing	 to	 include	
persons with suspected TB (i.e., TB suspects) as well12.	
However, routine HIV testing is not a component of the 
national TB control programmes in India and elsewhere, 
due to operational and cost constraints. Currently, the 
Revised National TB Control Programme (RNTCP) 
of	 India	 recommends	 risk-based	 referral	 for	 HIV	
testing of only those patients with high risk behaviour, 
other sexually-transmitted infections, or opportunistic 
conditions suggestive of HIV infection13. However, the 
RNTCP envisages implementing routine HIV testing 
for all patients with TB in a phased manner13.	 In	this	
scenario, the strategy of identifying a subgroup of 
patients presenting with TB for targeted HIV testing 
needs	 to	 be	 considered	 as	 a	 bridge	 approach	 until	
the	 WHO	 recommendations	 are	 operationalised.	 To	
demonstrate in principle the feasibility of this strategy, 
we sought to develop and validate a clinical prediction 
rule, based on simple clinical and laboratory findings, 
to identify the patients at high risk for HIV co-infection 
among those treated for active TB.
Material & Methods
Study population: This study was conducted at the 
All	 India	 Institute	 of	 Medical	 Sciences	 hospital,	
New Delhi, a tertiary level teaching hospital catering 
predominantly to low- and middle-income groups. The 
catchment area of this hospital includes the National 
Capital Territory of Delhi and the neighbouring states, 
mainly Uttar Pradesh, Bihar, Uttaranchal, Jharkhand, 
and Haryana. All patients aged 13 yr and above, treated 
for active TB during the period from January 1997 
through December 2003, in the outpatient clinics of the 
Department of Medicine and those hospitalised during 
this period for the treatment of TB were eligible for 
inclusion in the study. Patients were excluded if HIV 
testing was not performed at the time of diagnosis of 
TB or the result of HIV testing was unavailable.
 A diagnosis of TB was made as per criteria 
described previously14.	 At	 the	 time	 of	 diagnosis,	
details of presenting symptoms, physical findings, 
anthropometry, radiological features, and laboratory 
findings were collected using a pre-designed instrument. 
For the present study, these case records were reviewed 
retrospectively. The study protocol was reviewed and 
approved by the Institute Ethics Committee at the All 
India Institute of Medical Sciences, New Delhi.
HIV testing: After	 pretest	 counselling	 and	 obtaining	
informed consent, patients underwent HIV testing 
at the time of diagnosis of TB. HIV testing was 
performed using commercially available enzyme-
linked immunosorbent assay (ELISA) kits (Detect 
HIV-1/2, BioChem Immunosystems Inc., Montreal, 
Canada; UBI HIV 1/2 EIA, Beijing United Biomedical 
Co. Ltd., Beijing, China) to detect antibodies to HIV-
1 and HIV-2 in the serum, as per the WHO strategy 
II15. Initially, all serum samples were tested using 
one ELISA. Serum that was non-reactive on the first 
test was considered HIV-negative. All serum samples 
found reactive on the first test were retested with a 
second ELISA based on a different antigen preparation 
and/or test principle. Serum that was reactive on both 
tests was reported HIV-positive. In case of discordant 
results, tests were repeated with the two assays and 
concordant results after repeat testing were considered 
final.
Statistical analysis: Statistical analyses were performed 
using a statistical software package (SPSS for 
Windows, version 10.0.1, SPSS Inc., Chicago, USA). 
The study group was split once randomly a posteriori,	
using	 a	 computer-run	 random	 selection	 algorithm,	
into a training set (two-thirds) and a testing set (one-
third). Continuous variables were presented as mean 
± standard deviation (SD) or as median [interquartile 
range (IQR)]. Categorical variables were expressed as 
numbers with proportions, n (%).
 In the training set, we compared the baseline 
clinical, laboratory, and radiological characteristics of 
patients with HIV-TB with that of HIV-negative patients 
with TB. Continuous variables were compared using 
independent-samples	 t-test or Mann-Whitney U test, 
as appropriate. Categorical variables were compared 
by chi-squared test or Fisher’s exact test. The variables 
associated with HIV serostatus at P<0.1 significance 
level on univariate analyses were selected for 
multivariable analysis. To avoid overfitting16,	among	the	
selected variables only those deemed potentially useful 
for clinical prediction (based on potential availability 
under field conditions) were chosen for inclusion in the 
multivariable model. Likewise, only variables having 
≥10 outcome-points were considered16.
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 The chosen variables were entered as covariates to 
develop a multivariable logistic regression equation, 
by conditional backward step-wise elimination, with 
HIV serostatus as the outcome variable. For easy 
usage, all continuous covariates were dichotomised 
[using cut-offs identified from receiver-operating 
characteristic (ROC) curves17]	before	entering	into	the	
equation. Then weights were assigned to the variables 
retained in the final equation – the assigned weights 
were equal to their β coefficients rounded to the first 
decimal. The aggregate of these weighted-variables 
was expressed as a summary variable (SV), for each 
patient individually. An ROC curve was plotted with 
the SV as the test variable and HIV serostatus as the 
state variable. We identified the optimal cut-off of SV 
from the ROC curve as the point corresponding to the 
best trade-off between sensitivity and specificity. This 
value of SV constituted the prediction rule.
 In the testing set, the SV was calculated using the 
equation derived on the training set. Area under the 
ROC curve was used to assess the overall predictive 
performance	 of	 the	 SV	 in	 the	 testing	 set17.	 The	
prediction rule was applied on the testing set, and 
the corresponding sensitivity, specificity, positive 
and negative predictive values, and likelihood ratios 
were calculated using standard methods18.	Further,	 to	
define the appropriate use of the prediction rule, the 
posterior probabilities were estimated19 for several 
hypothetical populations with different levels of HIV 
seroprevalence (prior probability), ranging from 1 to 
50 per cent, among patients with TB.
Results
 A total of 1074 patients with TB, treated over the 
study period of seven years, in whom the result of HIV 
testing was available, were included. The random split 
yielded a training set of 711 (66%) patients including 
66 (9%) with HIV-TB and a testing set of 363 (34%) 
patients [HIV-TB 30 (8%) patients]. Characteristics of 
the patients in the two data sets were comparable except 
for a slight excess of pulmonary involvement, cervical 
lymphadenopathy, and miliary TB among patients with 
HIV-TB in the testing set; the body-mass index, mid-
arm circumference, total lymphocyte count, and serum 
albumin of patients with HIV-TB in the testing set were 
comparatively lower as compared to that with HIV-TB 
in	the	training	set	(Table	I).
 In the training set, on univariate analysis, the 
following variables were associated with the presence 
of	 HIV	 co-infection	 at	 P<0.1 significance level: 
increasing age; male gender; lower body-mass index, 
mid-arm	circumference,	and	triceps	skinfold	thickness;	
absence of pulmonary involvement, miliary disease, 
and cavity formation on chest radiograph; negative 
sputum-smear	and	tuberculin	skin	test	status;	presence	
of axillary, inguinal, mediastinal, and intra-abdominal 
lymphadenopathy, pleural effusion, and meningitis; 
and low levels of haemoglobin, total lymphocyte 
count, and serum albumin (Table I). Of these 19 
variables, presence of pulmonary involvement, miliary 
disease, cavity formation, pleural effusion, meningitis, 
intra-abdominal and mediastinal lymphadenopathy, 
sputum-smear	 status,	 and	 tuberculin	 skin	 test	 status	
were not considered for inclusion in the multivariable 
model; the remaining 10 variables were included in the 
multivariable model. In the training set, complete data 
for these 10 variables were available for 528 (74%) of 
711 patients, including 29 (5.5%) with HIV-TB.
 After stepwise elimination, five variables 
remained in the final multivariable equation (Table I). 
These variables were assigned their corresponding 
weights (as described under Methods), and the SV 
was expressed as, SV = (1.7 × male gender) + (2.3 × 
axillary lymphadenopathy) + (1.1 × triceps skinfold 
thickness < 8 mm) + (2 × haemoglobin <11 g/dl) + 
(1.3 × albumin < 3.5 g/dl); all variables were scored 
as 1 if present and 0 if not. In the training set, the area 
under the ROC curve was 0.87 (95% CI 0.79-0.95; 
Fig. A). The optimal trade-off between sensitivity and 
specificity was at a cut-off of SV > 2.4 (i.e.,	presence	of	
any two of the five variables in the equation), and the 
corresponding sensitivity and specificity for predicting 
HIV co-infection were 90 per cent (95% CI 79-100%) 
and 49 per cent (45-54%), respectively. This cut-off of 
SV	constituted	the	prediction	rule.	
	 In	 the	 testing	 set,	 complete	 data	 to	 calculate	 the	
SV were available for 286 (79%) patients, including 
18 (6%) with HIV-TB. After calculating the SV for 
these patients, the prediction rule was applied. The rule 
had a sensitivity of 94 per cent (17 of 18 patients; 95% 
CI 84-100%) and a specificity of 54 per cent (146 of 
268 patients; 49-60%). Corresponding positive and 
negative predictive values were 12 per cent (17 of 139 
patients; 7-18%) and 99 per cent (146 of 147 patients; 
98-100%). The positive and negative likelihood ratios 
were 2.07 (95% CI 1.75-2.46) and 0.10 (0.02-0.69), 
respectively. The area under the ROC curve in the 
testing set was 0.93 (95% CI 0.86-1.0; Fig. B).
 The effect of varying levels of prior probability 
of HIV co-infection among patients with TB on the 
performance	of	the	prediction	rule	is	presented	Table	II.	
The prediction rule was found to have a good negative 
predictive value in excess of 98 per cent in populations 
with prevalence rates of HIV co-infection ranging 1-10 
per cent among patients with TB (Table II).
Discussion
 We demonstrated in the present study that a simple 
clinical prediction rule based on clinical and laboratory 
parameters could be used to identify a subgroup of 
patients	at	high-risk	for	HIV	co-infection	among	those	
treated	for	TB.	Earlier,	another	prediction	rule	has	been	
derived in patients from Africa for similar purpose20,21.	
However, the earlier rule was based on radiographic	
findings, which are usually unavailable in the field 
setting.	In	contrast,	the	current	prediction	rule	is	based	
only on clinical and laboratory parameters that are 
readily available to the clinician at the time of initial 
evaluation of patients with TB. Further, it was found 
that the prediction rule derived in the current study had a 
good negative predictive value and could thus potentially 
obviate the need for HIV testing in more than half the 
patients under resource-poor settings, especially in the 
context	of	large	scale	national	TB	control	programmes.	
 As shown here, this would hold true particularly 
in populations with a prevalence of HIV co-infection 
ranging 1-10 per cent among patients with TB (The 
estimated prevalence of HIV co-infection among patients 
Table I. Comparison of characteristics between HIV co-infected (TB+ HIV+) and HIV-negative (TB+ HIV-) patients with tuberculosis
Characteristic Training data set (n = 711) Testing data set (n = 363) Unadjusted odds 
ratio* (95% CI)
Adjusted odds ratio*,†	
(95% CI)
TB+ HIV- 
n = 645
TB+ HIV+ 
N = 66
TB+ HIV- 
n = 333
TB+ HIV+ 
n = 30
Age, yr ‡,§ 32 ± 14 34 ± 9 31	±	13 37 ± 12 2.60 (1.50-4.49) 1.67 (0.56-5.01)
Male	gender	II 362 (56) 57 (86) 194 (58) 25 (83) 4.95 (2.41-10.17) 5.31 (1.52-18.61)
Duration of symptoms, wk¶ 12 (6-52) 12 (3-36) 16 (6-52) 6.5 (4-24) -- --
Body-mass index, kg/m2 ‡,§ 18.9 ± 3.6 17.8 ± 2.9 18.9 ± 3.8 16.0 ± 2.7 1.70 (0.78-3.66) 0.84 (0.26-2.74)
Mid-arm	circumference,	cm	‡,§ 22.6 ± 4.1 19.2 ± 4.4 22.9 ± 4.0 17.4 ± 3.3 2.84 (1.25-6.44) 1.79 (0.50-6.47)
Triceps	skinfold	thickness,	mm	‡,§ 8.8 ± 3.3 6.5	±	1.6 9.1 ± 3.2 6.3 ± 1.7 6.28 (2.54-15.49) 2.91 (0.95-8.89)
Pulmonary involvement II
  Cavity formation II,**
  Positive sputum-smear II
447 (69)
121 (27)
208 (32)
26 (39)
2 (8)
3	(5)
234 (70)
66 (28)
120 (36)
18 (60)
1	(6)
2 (7)
0.29 (0.17-0.49)
0.23 (0.05-0.96)
0.10 (0.03-0.32)
--
--
--
Lymphadenopathy II,††
            Cervical
            Axillary
												Inguinal
												Intra-abdominal
213 (33)
51 (8)
38 (6)
30 (5)
18 (27)
17 (26)
11 (17)
10 (15)
102 (31)
22 (7)
19 (6)
21 (6)
14 (47)
8 (27)
6 (20)
4	(13)
0.76 (0.43-1.34)
4.04 (2.17-7.52)
3.20 (1.55-6.60)
3.66 (1.70-7.88)
--
9.71 (3.24-29.10)
1.40 (0.30-6.60)
--
												Mediastinal 77 (12) 13 (20) 45	(14) 5 (17) 1.81 (0.94-3.47) --
Pleural effusion II 45 (7) 11 (17) 20 (6) 4	(13) 2.67 (1.31-5.45) --
Ascites	II 23 (4) 2 (3) 7 (2) 1	(3) 0.85 (0.20-3.67) --
Pericardial effusion II 14 (2) 1 (2) 10 (3) 0 (0) 0.69 (0.09-5.36) --
Meningitis	II 16 (2) 5 (8) 7 (2) 0 (0) 3.22 (1.14-9.10) --
Miliary tuberculosis II 90 (14) 4	(6) 39 (12) 4	(13) 0.40 (0.14-1.12) --
Haemoglobin,	g/dl	‡,§ 11.7 ± 2.2 10.1 ± 2.3 11.6 ± 2.4 8.8 ± 2.8 3.23 (1.74-5.98) 7.56 (2.48-23.05)
Total lymphocyte count, cells/μl ‡,§ 2454 ± 1132 1850 ± 707 2369 ± 820 1444 ± 974 3.76 (1.90-7.42) 1.97 (0.70-5.58)
Serum	albumin,	g/dl	‡,§ 4.1 ± 0.8 3.1 ± 0.7 4.1 ± 0.8 2.8 ± 0.7 9.99 (5.01-19.94) 3.67 (1.31-10.26)
Positive TST II,‡‡ 273 (42) 7 (11) 141 (42) 1	(3) 0.16 (0.07-0.36) --
Mid-arm circumference and triceps skinfold thickness were measured at midpoint between the acromion and olecranon processes of right arm 
using a non-elastic measuring tape and Lange skinfold calipers, respectively; mean of three consecutive readings was taken; anthropometric 
data were available for 917 (85%) of 1074 patients; data on haemoglobin and serum albumin were available for 996 (93%) and 917 (85%) 
of 1074 patients, respectively
* = estimated in the training data set; † = only those variables of potential use in field settings with P <0.1 were included in the multivariable 
analysis (see Methods); ‡ = data presented as mean ± SD; § = continuous variables were dichotomised for estimating odds ratios, using fol-
lowing cut-offs: age > 28 yr, body-mass index < 19 kg/m2, mid-arm circumference < 23 cm, triceps skinfold thickness < 8 mm, haemoglobin 
< 11 g/dl, total lymphocyte count < 2400/μl, and serum albumin < 3.5 g/dl; II = data expressed as number (%) of patients; ¶ = data presented 
as median (IQR); ** = denominator was no. of patients with pulmonary involvement; †† = lymph node enlargement of at least 1 cm across 
was considered significant; ‡‡ = defined as induration ≥ 10 mm in HIV-negative and ≥ 5 mm in HIV co-infected patients; -- = not included 
in the multivariable model; TST = tuberculin skin test (performed with 5 TU)
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Fig. Empirical receiver-operating characteristic curve for the summary variable to predict HIV co-infection in the training data set (A)	and	
the	testing	data	set	(B). (1-specificity) represents the rate of false-positive error.
(A) (B)
with TB in India is about 1.2%22). However, for obvious 
reasons, the subgroup of patients identified as high risk 
by the prediction rule would need further HIV testing 
for a diagnosis of HIV infection to be made. We would 
like to stress, where conditions permit, a non-selective 
testing strategy is the most preferred one for identifying 
patients with HIV-TB, and a convincing argument can 
be made in favour of non-selective testing over that of 
a targeted testing strategy. Notwithstanding, in reality 
only about 4 per cent of patients with TB in India get 
tested	for	HIV	co-infection22.
 As all consecutive patients with TB were included, 
there was no obvious selection bias. However, being a 
hospital-based study, the study population is likely to 
differ from that seen in primary care settings, where 
most of the patients with TB receive their treatment. 
It is possible that when compared to the primary care 
setting, patients might present in a tertiary care setting 
late during the course of illness and with comparatively 
advanced disease. But, this delay is likely to have 
been there in both the groups namely HIV-TB as well 
as HIV-negative patients with TB, and it is unclear 
how this delay would influence the performance of 
the prediction rule. In the present study, we sought 
to demonstrate only the feasibility of identifying a 
subgroup of patients with TB at high risk for HIV co-
infection. It needs to be emphasised that the findings 
of the present study cannot be directly extrapolated 
to	primary care settings. This approach has to be first 
validated specifically in a primary care setting before 
being	incorporated	into	practice.
 Overall, cavitary pulmonary disease, sputum-
smear positivity, and tuberculin skin test positivity 
were less common among patients with HIV-TB, and 
these findings were in consonance with the published 
literature23. On the contrary, miliary TB was found to 
be less common among patients with HIV co-infection 
in the present study. It is likely that due to the severity 
of the underlying disease, many of these patients 
succumbed to their illness before they could seek 
medical	attention.
 The factors found to be independently associated 
with HIV co-infection in the present study were 
reflective of either the risk factor for HIV infection 
(male gender) or the consequences of HIV infection 
(malnutrition and anaemia). It is well known that in 
India,	 unlike	 the	African	 countries,	 HIV	 infection	 is	
more common among men than women. Similarly, 
it is known that weight loss and malnutrition are 
more pronounced in patients with HIV-TB24.	Also,	 a	
progressive decline in haemoglobin level occurs as HIV 
disease advances25. In the present study, presence of 
axillary lymphadenopathy was found to be associated 
with HIV infection. An earlier study from Africa had 
made a similar observation26. Generalised non-specific 
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immune activation occurs in patients with HIV-TB23,	
and it probably accounts for this observed association.
	 Certain	 methodological	 issues	 merit	 attention.	
First, a positive Western blot assay is considered the 
gold standard for the confirmation of HIV infection. 
Diagnosis of HIV infection was made using sequential 
ELISA, in the present study. However, this is the strategy 
recommended by the WHO for symptomatic patients 
with suspected HIV infection15, and this strategy has 
been validated and found to have a positive predictive 
value similar to Western blot-based testing27.	Second,	
we did not evaluate the predictive value of clinical 
clues such as a history of high risk sexual behaviour 
and presence of mucosal candidiasis, since these were 
considered as compelling indications on their own to 
offer HIV testing to a patient with TB. Third, in the 
derivation of the multivariable model, we dichotomised 
the continuous variables before inclusion in the model. 
This could have resulted in a modest loss of statistical 
power to detect a relation between the variables and the 
outcome28. However, dichotomisation was necessary to 
facilitate easy use of the prediction rule under clinical 
settings.
 Finally, since the study was a retrospective analysis, 
validation was done by the split-group method. This 
represents a narrow validation of the prediction rule, and 
in the hierarchy of evidence proposed by the Evidence-
Based	 Medicine	 Working	 Group29, this would be 
considered Level 4 evidence. As pointed out earlier, it 
needs to be validated prospectively and independently 
in broader clinical settings, specifically in populations 
where it is intended to be used. The cut-offs for the 
various	parameters	in	the	prediction	rule	might	need	to	
be adjusted to suit the population of interest, so as to 
achieve the best predictive performance.
 In conclusion, male gender, presence of axillary 
lymphadenopathy, anaemia, hypoalbuminaemia, and 
reduced triceps skinfold thickness were associated with 
the presence of underlying HIV co-infection among 
patients with TB presenting to hospital setting. A 
simple clinical prediction rule based on these findings 
(presence of any two of these features) had a good 
negative predictive value and could be used to identify 
a subgroup of patients with TB for targeted HIV testing 
in resource-poor settings where universal access to 
HIV	testing	remains	limited.
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